Abstract
Botulinum toxin has long been known for its paralytic effects on the human voluntary musculature via inhibition of acetylcholine release at neuromuscular junctions. Its original clinical use for the treatment of strabismus has expanded significantly to include neurological conditions related to muscle hyperactivity and/or spasticity (e.g., dystonia, spasticity, tics, tremor, dysphonia). Recently, botulinum toxin has been shown to impact autonomic disorders by acting at acceptors on glands and smooth muscle, and consequently it has been used in the management of a number of other conditions including hypersecretory disorders, pain syndromes, detrusor sphinchter dyssenergia or overactivity and gastointestinal smooth muscle/sphincter spasm; it may also reduce pain in patients for whom it is used to treat these and other primary conditions. This article will review the pharmacology and formulations of botulinum toxins as well as data from clinical trials demonstrating their efficacy for numerous conditions based on their effects on cholinergic synapses outside the motor nervous system.
Current Pharmaceutical Design
Title: Current Clinical Applications of Botulinum Toxin
Volume: 15 Issue: 31
Author(s): Daniel D. Truong, Andrea Stenner and Gerhard Reichel
Affiliation:
Abstract: Botulinum toxin has long been known for its paralytic effects on the human voluntary musculature via inhibition of acetylcholine release at neuromuscular junctions. Its original clinical use for the treatment of strabismus has expanded significantly to include neurological conditions related to muscle hyperactivity and/or spasticity (e.g., dystonia, spasticity, tics, tremor, dysphonia). Recently, botulinum toxin has been shown to impact autonomic disorders by acting at acceptors on glands and smooth muscle, and consequently it has been used in the management of a number of other conditions including hypersecretory disorders, pain syndromes, detrusor sphinchter dyssenergia or overactivity and gastointestinal smooth muscle/sphincter spasm; it may also reduce pain in patients for whom it is used to treat these and other primary conditions. This article will review the pharmacology and formulations of botulinum toxins as well as data from clinical trials demonstrating their efficacy for numerous conditions based on their effects on cholinergic synapses outside the motor nervous system.
Export Options
About this article
Cite this article as:
Truong D. Daniel, Stenner Andrea and Reichel Gerhard, Current Clinical Applications of Botulinum Toxin, Current Pharmaceutical Design 2009; 15 (31) . https://dx.doi.org/10.2174/138161209789271843
DOI https://dx.doi.org/10.2174/138161209789271843 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ion Pore Formation in Lipid Bilayers and Related Energetic Considerations
Current Medicinal Chemistry Dopaminergic Modulation of Cognitive Control: Distinct Roles for the Prefrontal Cortex and the Basal Ganglia
Current Pharmaceutical Design Proteomic Analysis of Phosphorylation in the Brain
Current Proteomics Extrasynaptic GABA and Glutamate Receptors in Epilepsy
CNS & Neurological Disorders - Drug Targets The Applications of Pharmacogenomics to Neurological Disorders
Current Molecular Medicine Pharmacology of the Intracellular Pathways Activated by Amyloid Beta Protein
Mini-Reviews in Medicinal Chemistry Fc Receptor Signaling in Leukocytes: Role in Host Defense and Immune Regulation
Current Immunology Reviews (Discontinued) Animal Models for Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Glial Reaction in Parkinsons Diseases: Inflammatory Activation Signaling of Glia as a Potential Therapeutic Target
Current Signal Transduction Therapy Synthesis, Characterization, in vivo and in silico Studies of Antidepressant Activity of 2-chloro-4’methoxy Benzoin
Current Chemical Biology Chromosomal Micro-aberration in a Saudi Family with Juvenile Myoclonic Epilepsy
CNS & Neurological Disorders - Drug Targets Nano-Enabled Tribological Thin Film Coatings: Global Patent Scenario
Recent Patents on Nanotechnology Editorial (Thematic Issue: The Multidomain Mobility Lab in Older Persons: From Bench to Bedside)
Current Pharmaceutical Design Vital Elements of the Wnt-Frizzled Signaling Pathway in the Nervous System
Current Neurovascular Research Dual Carbonic Anhydrase - Cyclooxygenase-2 Inhibitors
Current Topics in Medicinal Chemistry Onychomycosis: Current Understanding and Strategies for Enhancing Drug Delivery into Human Nail Tissue
Current Drug Research Reviews Metabotropic Glutamate Receptors as Therapeutic Targets for Cognitive Disorders
Current Topics in Medicinal Chemistry Editorial [Hot Topic:Ion Channels as a Target for Drug Design (Executive Editor: Kwok-Keung Tai)]
Current Pharmaceutical Design (Pro)renin Receptor as a New Drug Target
Current Pharmaceutical Design Non-Steroidal Anti-Inflammatory Drugs as Anti-Amyloidogenic Compounds
Current Pharmaceutical Design